ArticlePharmaceutics2023
Preparation and In Vitro Characterization of Microneedles Containing Inclusion Complexes Loaded with Progesterone.
Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 8 citations in OpenAlex.
- Programmable Paracrine-Mimetic Microneedle System for Temporal Regulation of Cardiac Repair.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Traditional Chinese medicine ingredients integrated microneedles: A promising strategy for transdermal treatment.Asian journal of pharmaceutical sciences · 2026Review
- Thermal-enhanced self-heating microneedle patch for sustained progesterone delivery and improved pregnancy maintenance.Materials today. Bio · 2026Article
- In vitro Evaluation of Hydroxypropyl-β-cyclodextrin Effects on Rhein Flux Across Microneedle-pretreated Skin.AAPS PharmSciTech · 2026Article
- Nanotechnology strategies for endometrium health: Are we on the right track?Bioactive materials · 2025Review
- Microneedles as a Promising Technology for Disease Monitoring and Drug Delivery: A Review.ACS materials Au · 2025Review
- A Progesterone Microneedle Patch for Self-Administration in the Prevention of Preterm Birth in a Mouse Model.Drug design, development and therapy · 2025Article
- Development of Norelgestromin Dissolving Bilayer Microarray Patches for Sustained Release of Hormonal Contraceptive.Pharmaceutics · 2024Article
- Novel Drug Delivery Systems: An Important Direction for Drug Innovation Research and Development.Pharmaceutics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
objectiveIn order to improve patient compliance and the ease of use during progesterone application, and to increase the clinical application of progesterone, progesterone was made into a microneedle.
methodsProgesterone complexes were prepared using a single-factor and central composite design. In the preparation of the microneedles, the tip loading rate was used as an evaluation index. The selection of tip materials among the biocompatible materials of gelatin (GEL), hyaluronic acid (HA), and polyvinylpyrrolidone (PVP), and the use of polyvinyl alcohol (PVA) and hydroxypropyl cellulose (HPC) as backing layers, respectively, were carried out and the resulting microneedles were evaluated accordingly.
resultsThe progesterone inclusion complexes prepared at a molar ratio of 1:2.16 progesterone and hydroxypropyl-β-cyclodextrin (HP-β-CD), a temperature of 50 °C, and reaction time of 4 h had high encapsulation and drug-loading capacities of 93.49% and 9.55%, respectively. Gelatine was finally chosen as the material for the preparation of the micro-needle tip based on the drug loading rate of the tip. Two types of microneedles were prepared: one with 7.5% GEL as the tip and 50% PVA as the backing layer, and one with 15% GEL as the tip and 5% HPC as the backing layer. The microneedles of both prescriptions exhibited good mechanical strength and penetrated the skin of rats. The needle tip loading rates were 49.13% for the 7.5% GEL-50% PVA microneedles and 29.31% for the 15% GEL-5% HPC microneedles. In addition, in vitro release and transdermal experiments were performed using both types of microneedles.
conclusionThe microneedles prepared in this study enhanced the in vitro transdermal amount of progesterone drug by releasing the drug from the microneedle tip into the subepidermis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.